A Major Project in Canada

Guided by various local experts and spearheaded by GC Biotherapeutics Inc. (GCBT), Project Oasis is a plan to expand GC’s business to North America and Europe. Its Montreal plant will be the project’s focal point. $400 million will be invested in Canada`s only intravenous immunoglobulin (IVIG) and albumin manufacturing plant and in sourcing essential raw materials. We are honoured to receive strategic support from Investissement Quebec and that the Korean National Pension Services has invested in us.

Construction of our facility began in the 2nd quarter of 2015. It will comply with the current US and Canadian Good Manufacturing Practices (cGMP). With a solid foundation accumulated during the development of similar plants worldwide, our experts will successfully transfer innovative technology and process equipment. Our plasma fractionation facility will be equipped with state-of-the-art filling and packaging areas to finalize bulk products for commercial use.

GCBT will consist of more than 200 highly qualified scientists, technical professionals, and sales representatives who will all contribute to the production and distribution of plasma protein products from a facility with an initial capacity to process 1 million litres of plasma annually.

We are expecting to serve the market in Canada, United States and China with our products in the short-midterm.

View Gallery

Key Milestones

Conceptual design completion January 2015
Basic design completion April 2015
Ground-breaking June 2015
Building completion Q3, 2016
Plant opening October 2017

Project Highlights

Investment size $400 million
Number of employees (2019) More than 200
Initial facility capacity 1 million litres of plasma
Plant Location Technoparc Montreal (St-Laurent Borough)
Land Area
Building Area
770 000 sq. ft.
225,000 sq. ft.
Products –       IVIG 10%
–       Albumin 5%
–       Albumin 20%
–       Albumin 25%
–       Other Bio-products to be          added

Back to Top